We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+46.74%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.57B
AUM Growth
+$1.21B
Cap. Flow
+$318M
Cap. Flow %
8.9%
Top 10 Hldgs %
45.04%
Holding
142
New
39
Increased
22
Reduced
59
Closed
10

Top Buys

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$68.1M
2
GBIO
Generation Bio
GBIO
+$62.7M
3
RPRX icon
Royalty Pharma
RPRX
+$37.1M
4
ONC
BeOne Medicines Ltd
ONC
+$32.6M
5
NG icon
NovaGold Resources
NG
+$26.3M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$137M
2
AVTR icon
Avantor
AVTR
+$40.7M
3
PYPL icon
PayPal
PYPL
+$33.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27M
5
Z icon
Zillow
Z
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 61.98%
2 Consumer Discretionary 13.38%
3 Technology 3.16%
4 Financials 1.15%
5 Communication Services 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAL icon
26
CALL
Delta Air Lines
DAL
$57.1B
$35.1M 0.98%
+1,250,000
New +$31.8M
PYPL icon
27
PayPal
PYPL
$50.4B
$34.8M 0.98%
200,000
-240,000
-55% -$33.2M
GOSS icon
28
Gossamer Bio
GOSS
$92.8M
$34.6M 0.97%
2,658,968
+850,000
+47% +$10.7M
TGTX icon
29
TG Therapeutics
TGTX
$8.16B
$34.1M 0.95%
1,750,000
+750,000
+75% +$12.1M
AVTR icon
30
Avantor
AVTR
$9.68B
$34M 0.95%
2,000,000
-2,500,000
-56% -$40.7M
MRNA icon
31
Moderna
MRNA
$21.7B
$32.1M 0.9%
500,000
-2,500,000
-83% -$137M
XLI icon
32
CALL
State Street Industrial Select Sector SPDR ETF
XLI
$32.2B
$30.9M 0.87%
450,000
-150,000
-25% -$9.73M
EPZM
33
DELISTED
Epizyme, Inc
EPZM
$30.1M 0.84%
1,875,000
-425,000
-18% -$7.42M
TBIO
34
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$28.7M 0.8%
1,600,000
+1,000,000
+167% +$15.1M
Z icon
35
Zillow
Z
$7.81B
$27.8M 0.78%
483,000
-417,000
-46% -$20.7M
ABBV icon
36
CALL
AbbVie
ABBV
$471B
$24.5M 0.69%
+250,000
New +$22M
NG icon
37
NovaGold Resources
NG
$2.52B
$23.9M 0.67%
+2,600,000
New +$26.3M
BAC icon
38
CALL
Bank of America
BAC
$433B
$23.8M 0.66%
1,000,000
-1,000,000
-50% -$23.6M
RUBY
39
DELISTED
Rubius Therapeutics, Inc
RUBY
$23M 0.64%
3,852,341
-31,450
-0.8% -$186K
TPTX
40
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$22.6M 0.63%
350,000
+50,000
+17% +$2.88M
AGIO icon
41
Agios Pharmaceuticals
AGIO
$2.08B
$20.1M 0.56%
376,000
-24,000
-6% -$1.11M
AAL icon
42
American Airlines Group
AAL
$9.96B
$19.6M 0.55%
+1,500,000
New +$18.2M
BBIO icon
43
BridgeBio Pharma
BBIO
$16.5B
$19.6M 0.55%
600,000
+50,000
+9% +$1.52M
ADVM
44
DELISTED
Adverum Biotechnologies
ADVM
$18.8M 0.53%
90,000
+30,000
+50% +$5.31M
MRSN
45
DELISTED
Mersana Therapeutics
MRSN
$18.7M 0.52%
+32,000
New +$10.9M
REPL icon
46
Replimune Group
REPL
$426M
$18.6M 0.52%
750,000
+150,000
+25% +$2.65M
RPTX
47
DELISTED
Repare Therapeutics
RPTX
$18.6M 0.52%
+600,000
New +$19.3M
TECH icon
48
Bio-Techne
TECH
$11.2B
$17.2M 0.48%
+260,000
New +$15.6M
KYNB
49
Kyntra Bio
KYNB
$28.1M
$16.2M 0.45%
16,000
-8,000
-33% -$7.43M
ARAV
50
DELISTED
Aravive, Inc. Common Stock
ARAV
$16.1M 0.45%
1,380,306
-69,694
-5% -$827K
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2020 Portfolio in Review

As of Q2 2020, Artal Group held 142 positions worth $3.57B, up 51% from $2.37B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group deployed $318M of net new capital in Q2 2020, opening 39 new positions and adding to 22 existing holdings. Its largest new stake was GDS Holdings: 1,100,000 shares worth $87.6M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 69% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Moderna, an estimated $137M trimmed.

  • Artal Group's largest Q2 2020 buy was GDS Holdings: 1,100,000 shares worth $87.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q2 2020, an estimated $32.6M increase.
  • Artal Group's biggest Q2 2020 reduction was Moderna, cutting an estimated $137M.
  • Artal Group fully exited Arrowhead Research in Q2 2020, selling an estimated $17.3M.
  • Artal Group's ten largest holdings make up 45% of its $3.57B portfolio in Q2 2020.
  • Artal Group opened 39 new positions and closed 10 in Q2 2020.
  • Artal Group's portfolio value rose 51% quarter-over-quarter to $3.57B.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.